101 Therapeutics to Present Phase 2/3 Data on Macrophage-Targeted, Steroid-Sparing Glucocorticoid 101-PGC-005 at ACR Convergence 2026
October 20, 2026 · 2:46 PM · ENGLEWOOD, N.J.
CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone in 309-patient Phase 2/3 trial (HR 2.31); steroid-sparing data at ACR Poster 0122, Nov 8...
- PublishedOctober 20, 2026 · 2:46 PM
- LocationENGLEWOOD, N.J.
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →